Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled NC-107 (CBD) for Generalized Anxiety Disorder
NCT06656806Phase 1Not yet recruiting
- Sponsor
- Trinity Hypertension & Metabolic Research Institute
- Start
- Dec 2024
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in generalized anxiety disorder (GAD) comparing Inhaled NC-107 with Placebo (2 arms). Primary endpoint: Concentration of CBD in plasma at 4 weeks. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
cannabidiol
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT06656806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06656806.